Xueqin Sherine Sun

Dr. Xueqin Sherine Sun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Nature
Verified
Journal Article
Closed access
PDF file
XSXueqin Sherine Sun
Xueqin Sherine Sun
OKOlaf Klingbeil
Olaf Klingbeil
BLBin Lu
Bin Lu
CWCaizhi Wu
Caizhi Wu
CBCarlos Ballon
Carlos Ballon
AMAlea A Mills
Alea A Mills

3 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
LHLaurence Haddadin
Laurence Haddadin
XSXueqin Sherine Sun
Xueqin Sherine Sun
Stem cells have emerged as a pivotal area of research in the field of oncology, offering new insights into the mechanisms of cancer initiation, progression, and resistance to therapy. This review provides a comprehensive overview of the role of stem cells in cancer, focusing on cancer stem cells (CSCs), their characteristics, and their implications for cancer therapy. We discuss the origin and identification of CSCs, their role in tumorigenesis, metastasis, and drug resistance, and the potential therapeutic strategies targeting CSCs. Additionally, we explore the use of normal stem cells in cancer therapy, focusing on their role in tissue regeneration and their use as delivery vehicles for anticancer agents. Finally, we highlight the challenges and future directions in stem cell research in cancer.

21 July 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
SBSeamus Balinth
Seamus Balinth
MFMatthew L. Fisher
Matthew L. Fisher
YHYon Hwangbo
Yon Hwangbo
CWCaizhi Wu
Caizhi Wu
CBCarlos Ballon
Carlos Ballon
AMAlea A Mills
Alea A Mills

11 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HLHeng Liang
Heng Liang
MFMatthew L Fisher
Matthew L Fisher
CWCaizhi Wu
Caizhi Wu
CBCarlos G Ballon
Carlos G Ballon
XSXueqin Sherine Sun
Xueqin Sherine Sun
AMAlea A Mills
Alea A Mills
Protein arginine methyltransferase 5 (PRMT5) is a critical oncogenic factor in various cancers, and its inhibition has shown promise in suppressing tumor growth. However, the role of PRMT5 in squamous cell carcinoma (SCC) remains largely unexplored. In this study, we analyzed SCC patient data from The Cancer Genome Atlas (TCGA) and the Cancer Dependency Map (DepMap) to investigate the relationship between PRMT5 and SCC proliferation. We employed competition-based cell proliferation assays, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays, flow cytometry, and in vivo mouse modeling to examine the regulatory roles of PRMT5 and its binding partner WDR77 (WD repeat domain 77). We identified downstream targets, including the p63 isoform ΔNp63α and the cyclin-dependent kinase inhibitor p21, through single-cell RNA-seq, RT-qPCR, and Western blot analyses. Our findings demonstrate that upregulation of PRMT5 and WDR77 correlates with the poor survival of head and neck squamous cell carcinoma (HNSCC) patients. PRMT5/WDR77 regulates the HNSCC-specific transcriptome and facilitates SCC proliferation by promoting cell cycle progression. The PRMT5 and WDR77 stabilize the ΔNp63α Protein, which in turn, inhibits p21. Moreover, depletion of PRMT5 and WDR77 repress SCC in vivo. This study reveals for the first time that PRMT5 and WDR77 synergize to promote SCC proliferation via the ΔNp63α-p21 axis, highlighting a novel therapeutic target for SCC.